Literature DB >> 24052118

Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy.

Nolwenn Le Saché1, Mickael Afanetti, Kumaran Deiva, Laurent Chevret, Pierre Tissières.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24052118     DOI： 10.1007/s00415-013-7107-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

Review 1.  The effects of rituximab on immunocompetency in patients with autoimmune disease.

Authors:  R John Looney; Renganathan Srinivasan; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2008-01

Review 2.  Gram-positive toxic shock syndromes.

Authors:  Emma Lappin; Andrew J Ferguson
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

3.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

4.  Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus.

Authors:  Dennis L Stevens; Yongsheng Ma; Daniel B Salmi; Eric McIndoo; Randi J Wallace; Amy E Bryant
Journal:  J Infect Dis       Date:  2006-12-18       Impact factor: 5.226

5.  Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy Fleischmann; Daniel E Furst; Katherine Macey; Marianne Sweetser; Ariella Kelman; Ravi Rao
Journal:  J Rheumatol       Date:  2010-01-28       Impact factor: 4.666

Review 6.  NMDA receptor antibody encephalitis.

Authors:  Sarosh R Irani; Angela Vincent
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 7.  Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.

Authors:  P M Schlievert
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

8.  Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.

Authors:  Jessica Darenberg; Nahla Ihendyane; Jan Sjölin; Ewa Aufwerber; Sven Haidl; Per Follin; Jan Andersson; Anna Norrby-Teglund
Journal:  Clin Infect Dis       Date:  2003-07-17       Impact factor: 9.079

9.  Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.

Authors:  Marko Kavcic; Brian T Fisher; Alix E Seif; Yimei Li; Yuan-Shung Huang; Dana Walker; Richard Aplenc
Journal:  J Pediatr       Date:  2012-12-24       Impact factor: 4.406
  9 in total
  1 in total

1.  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Authors:  Russell C Dale; Fabienne Brilot; Lisa V Duffy; Marinka Twilt; Amy T Waldman; Sona Narula; Eyal Muscal; Kumaran Deiva; Erik Andersen; Michael R Eyre; Despina Eleftheriou; Paul A Brogan; Rachel Kneen; Gulay Alper; Banu Anlar; Evangeline Wassmer; Kirsten Heineman; Cheryl Hemingway; Catherine J Riney; Andrew Kornberg; Marc Tardieu; Amber Stocco; Brenda Banwell; Mark P Gorman; Susanne M Benseler; Ming Lim
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.